Exagen Inc. Gains 42.38%
Exagen Inc. (XGN:NASDAQ) rocketted at $2.99, a gain of 42.4%. On Tue, Nov 15, 2022, XGN:NASDAQ touched a New 2-Week High of $2.99. The stock got featured on our News Catalysts scanner on Mon, Nov 14, 2022 at 05:35 PM in the 'EARNINGS' category. From Tue, Nov 01, 2022, the stock recorded 30.00% Up Days and 45.45% Green Days
About Exagen Inc. (XGN:NASDAQ)
Exagen Diagnostics Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets four products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. It processed approximately 9,300 patient specimens for its diagnostic product line, Avise SLE. It markets and sells solutions to community rheumatologists.
Top 10 Gainers:
- SatixFy Communications Ltd. (SATX:NYSEMKT), 140.73%
- Tenax Therapeutics, Inc. (TENX:NASDAQ), 45.74%
- Exagen Inc. (XGN:NASDAQ), 42.38%
- Gelesis Holdings Inc. (GLS:NYSE), 40.03%
- 4D Molecular Therapeutics Inc. (FDMT:NASDAQ), 38.55%
- HUYA Inc. (HUYA:NYSE), 38.26%
- WiMi Hologram Cloud Inc. (WIMI:NASDAQ), 37.32%
- Sea Limited (SE:NYSE), 36.05%
- SenesTech, Inc. (SNES:NASDAQ), 35.82%
- Perfect Corp. Class A (PERF:NYSE), 33.2%